The Heart Failure Paradox: An Epidemic of Scientific Success

Jessup, Mariell

doi:10.1161/cir.0000000000000065

Cited by 12 publications

(6 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 She also chaired the panel that wrote the 2009 American College of Cardiology/American Heart Association (AHA) guidelines update on managing heart failure, 13 led the AHA's Scientific Sessions program committee in 2009 and 2010, and served as AHA president in 2013-2014. 14 Recently, she stepped down as the cochair of the American College of Cardiology/AHA prevention guidelines panel and chair of the AHA's science and clinical education lifelong learning committee.…”

Section: Profiles In Cardiovascular Sciencementioning

confidence: 99%

Mariell Jessup

Patterson¹

2017

Circulation Research

View full text Add to dashboard Cite

Section: Profiles In Cardiovascular Sciencementioning

confidence: 99%

Mariell Jessup

Patterson¹

2017

Circulation Research

View full text Add to dashboard Cite

“…On the basis of the results of the SENIOR study, nebivolol is safe and effective in elderly patients with HF, some of whom have mildly reduced or preserved ejection fraction. 73 , 75 , 76 Taking into account the limited effectiveness of traditional RAS inhibitors in the treatment of HF with preserved ejection fraction, particularly in women, 40 these results suggests a great potential of nebivolol in the treatment of these patients. Vinereanu and colleages 114 compared the effects of 6 months of therapy with either nebivolol or metoprolol on the left ventricular function of hypertensive patients.…”

Section: Introductionmentioning

confidence: 99%

“…This is an important consideration, as HF admissions to community hospitals pose a significant burden to the health care system, given the fact that readmission rates average 90 days postdischarge and 30-day mortality rates remain quite high. 40 …”

Section: Introductionmentioning

confidence: 99%

“… 56 These later findings are of particular relevance, as left ventricular diastolic dysfunction, prevalent in hypertensive women, has proven highly resistant to treatment with ACEIs or even ARBs. 40 Studies in animal models show that nebivolol augments vascular NO release, 57 and data obtained from individuals with essential hypertension indicate that nebivolol treatment dilates forearm vasculature 58 and reverses endothelial dysfunction. 59 Nebivolol has also been shown to reduce QT dispersion in hypertensive patients with left ventricular hypertrophy after 4 weeks of treatment, an effect that did not correlate with BP reduction.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan

Varagić¹,

Punzi²,

Ferrario³

2014

IBPC

View full text Add to dashboard Cite

Despite significant advances in pharmacologic approaches to treat hypertension during the last decades, hypertension- and hypertension-related organ damage are still a high health and economic burden because a large proportion of patients with hypertension do not achieve optimal blood pressure control. There is now general agreement that combination therapy with two or more antihypertensive drugs is required for targeted blood pressure accomplishment and reduction of global cardiovascular risk. The goals of combination therapies are to reduce long-term cardiovascular events by targeting different mechanism underlying hypertension and target organ disease, to block the counterregulatory pathways activated by monotherapies, to improve tolerability and decrease the adverse effects of up-titrated single agents, and to increase persistence and adherence with antihypertensive therapy. Multiple clinical trials provide evidence that fixed-dose combinations in a single pill offer several advantages when compared with loose-dose combinations. This review discusses the advances in hypertension control and associated cardiovascular disease as they relate to the prospect of combination therapy targeting a third-generation beta (β) 1-adrenergic receptor (nebivolol) and an angiotensin II receptor blocker (valsartan) in fixed-dose single-pill formulations.

show abstract

“…Chronic heart failure (CHF) remains a leading cause of cardiovascular mortality and morbidity that is characterized steadily arised worldwide [ 1 ]. As expected, significant improvements in survival have occurred for patients with CHF, with an increasing array of therapeutic options sharing quite varied properties of cost, invasiveness, and impact on life expectancy [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

The utility of biomarker risk prediction score in patients with chronic heart failure

et al. 2015

View full text Add to dashboard Cite

BackgroundChronic heart failure (CHF) has been remained a leading cause of cardiovascular morbidity and mortaluty. The risk stratification of CHF individuals based on clinical criteria and biomarkers' models may improve medical care and probably increase efficacy of treatment strategy. However, various predictive models approved for CHF patients appear to be distinguished in their prognostications. The study aim was to evaluate whether biomarker risk prediction score is powerful tool for risk assessment of three-year fatal and non-fatal cardiovascular events in CHF patients.MethodsIt was studied prospectively the incidence of fatal and non-fatal cardiovascular events in a cohort of 388 patients with ischemic-induced CHF within 3 years. Circulating biomarkers were collected at baseline of the study.ResultsIndependent predictors of clinical outcomes in patients with CHF were NT-pro-BNP, galectin-3, hs-CRP, osteoprotegerin, CD31+/annexin V+ endothelail-derived microparticles (EMPs) and CD31+/annexin V+ EMPs to CD14+CD309+ monuclear progenitor cells (MPCs) ratio. Index of cardiovascular risk was calculated by mathematical summation of all ranks of independent predictors, which occurred in the patients included in the study. Kaplan-Meier analysis showed that patients with CHF and the magnitude of the risk of less than 4 units have an advantage in survival when compared with patients for whom obtained higher values of cardiovascular risk score ranks.ConclusionBiomarker risk score for cumulative cardiovascular events, constructed by measurement of circulating NT-pro-BNP, galectin-3, hs-CRP, osteoprotegerin, CD31+/annexin V+ EMPs and CD31+/annexin V+ EMPs to CD14+CD309+ MPCs ratio, allowing reliably predict the probability survival of patients with CHF.

show abstract

The Heart Failure Paradox: An Epidemic of Scientific Success

Cited by 12 publications

References 69 publications

Mariell Jessup

Mariell Jessup

Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan

The utility of biomarker risk prediction score in patients with chronic heart failure

Contact Info

Product

Resources

About